Health and Healthcare Systems

The anti-obesity protein

People make their way through snow in New York's Times Square, February 8, 2013. A blizzard slammed into the northeastern United States on Friday, snarling traffic, disrupting thousands of flights and prompting five governors to declare states of emergency in the face of a fearsome snowstorm. REUTERS/Keith Bedford (UNITED STATES - Tags: ENVIRONMENT TPX IMAGES OF THE DAY) - RTR3DIUQ

Obesity is one of the biggest health problems afflicting the US. Image: REUTERS/Keith Bedford

Dom Galeon
Writer, Futurism

Deadly Combo

According to the World Health Organization (WHO), obesity is one of the most common health conditions in the world. It affects more than 600 million adults and around 41 million children under the age of 5. Of these, more than 29 million are in the United States, according to the Center for Disease Control and Prevention (CDC).

The consequences of obesity can be as serious as heart disease, stroke, some types of cancer, and type 2 diabetes, which the CDC reports around 29 million Americans have. Now, researchers from the Catholic University of Louvain in Belgium may have found a way to halt the development of both type 2 diabetes and obesity in humans, using a recently discovered protein.

 Image 1
Image: Lancet Journal

For 10 years now, scientists Patrice Cani, a WELBIO researcher at the Louvain Drug Research Institute, and Willem de Vos of the University of Wageningen in the Netherlands, have been studying a bacterium called Akkermansia muciniphila, and have realized that this bacteria is found in smaller levels in obese mice. Treating mice with A. muciniphila seemed to reverse several metabolic disorders that led to obesity.

An Unexpected Discovery

In a study published in the journal Nature Medicine, Cani and de Vos discovered something more. Since December 2015, Akkermansia-based treatment trials for humans have been ongoing. While the effects are yet to be conclusive, it’s clear that the treatment isn’t harmful to humans — after all, A. muciniphila is one of the more common gut bacteria.

Then something came up. They discovered that pasteurization had very positive effects on the bacterium. “Unexpectedly, we discovered that pasteurization of A. muciniphila enhanced its capacity to reduce fat mass development, insulin resistance and dyslipidemia in mice,” says the study.

Pasteurization, it would seem, makes the bacterium effective because it kills off everything else in A. muciniphila except for a protein — the genetically engineered version of it is called Amuc_1100. When tested on mice, this protein appeared to be good for the immune system, blocking toxins from reaching the bloodstream, and strengthening intestinal immunity.

Amuc_1100 is the key to how A. muciniphila can combat obesity in mice. In the near future, it’s expected to be able to do the same thing in humans.

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Stay up to date:

Biotechnology

Related topics:
Health and Healthcare SystemsGlobal Risks
Share:
The Big Picture
Explore and monitor how Biotechnology is affecting economies, industries and global issues
World Economic Forum logo

Forum Stories newsletter

Bringing you weekly curated insights and analysis on the global issues that matter.

Subscribe today

These collaborations are already tackling climate-driven health risks but more can be done to find solutions

Fernando J. Gómez and Elia Tziambazis

December 20, 2024

Investing in children’s well-being: The urgent need for expanded mental health and psychosocial support funding

About us

Engage with us

  • Sign in
  • Partner with us
  • Become a member
  • Sign up for our press releases
  • Subscribe to our newsletters
  • Contact us

Quick links

Language editions

Privacy Policy & Terms of Service

Sitemap

© 2024 World Economic Forum